India plans to cap prices on 18 new branded essential drugs

16 November 2015

Around 2.7 million people tend to die of cardiovascular problems annually in India. With the figure projected to soar by 1.5 million by 2030, non-communicable diseases and their risk factors are turning out to be the leading cause of mortality, reports The Pharma Letter’s India correspondent.

The World Health Organization had noted that the probability of a 30-70 year old Indian dying from the four main non-communicable diseases (NCDs) - diabetes, cancer, stroke and respiratory diseases - is 26%. NCDs are estimated to have accounted for 60% of all deaths in 2014.

In order to arrest the slide, the National Pharmaceutical Pricing Authority (NPPA) has capped the prices of 18 new brands of essential drugs, in a bid to make them cheaper and accessible to patients. The Indian health ministry has also identified the Indian Council of Medical Research (ICMR) as a nodal agency to conduct a survey that will monitor national NCDs targets in the country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK